why choose us

First received: July 12, 2022

Clinical Trial: TAB014 Compared to Lucentis® in Patients With Neovascular Age-related Macular Degeneration

Study Status: Completed

Recruit Status: RECRUITING

Condition: Neovascular Age-related Macular Degeneration

Study Type: INTERVENTIONAL


Official Title: A Phase III, Randomized, Multicenter, Doubled-blind Clinical Trial Comparing the Efficacy and Safety of TAB014 and Lucentis in Neovascular Age-related Macular Degeneration (nAMD) Patients

Brief Summary: This study is a randomized, multi-center, double blind, Lucentis controlled non-inferiority study in neovascular age-related macular degeneration patients.The objective of this study is to compare the efficacy and safety of TAB014 and ranibizumab (Lucentis).

Read more